Received Nov 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER LIVE (ZOSTAVAX) | MERCK & CO. INC. | UNK | — | — |
| VARZOS | ZOSTER LIVE (ZOSTAVAX) | MERCK & CO. INC. | UNK | — | — |
She reports that this year she came down with Shingles. She was diagnosed on 3/17/2025, but started seeing symptoms of it 5 to 7 days prior to that date. She did not have an extensive breakout; This spontaneous report was received from a patient referring to herself a 73-year-old female patient. The patient's medical history, concurrent conditions, concomitant therapies, previous drugs reactions and allergies were not reported. On an unknown date in 2014, the patient was vaccinated with zoster vaccine live (ZOSTAVAX), solution for injection, administered as prophylaxis (strength, Lot No., expiration date, dose number, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided); reconstituted with sterile diluent, solution for injection (Lot No., expiration date, route and indication were not provided). On 10-Mar-2025 (reported as was diagnosed on 17-MAR-2025, but started seeing symptoms of it 5 to 7 days prior to that date), the patient experienced came down with shingles, and it was stated that she did not have an extensive breakout (herpes zoster). Additionally, it was stated that her physician prescribed her an anti-viral as treatment for the event. At the reporting time, the outcome of the event of herpes zoster was not provided. The causal relationship between the event of herpes zoster with the suspect vaccine and the sterile diluent was not provided.